Non-small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis By Drug (Alimta, Iressa, Avastin, Tarceva, Zykadia, Tagrisso, Xalkori, Cyramza, Opdivo, Alecensa), By Region And Segment Forecasts 2014 - 2025

  • ID: 4209737
  • Report
  • Region: Global
  • 100 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline (GSK) Plc
  • Novartis
  • Pfizer, Inc.
  • MORE

The global non-small cell lung cancer therapeutics market is expected to reach a value of USD 12.2 billion by 2025. The non-small cell cancer therapeutics (NSCLC) market is anticipated to witness significant growth during the forecast period. This can be attributed to the high investment by market players in the research and development of lung cancer therapy, presence of a rich pipeline, and increasing penetration of drugs during the forecast period.

Introduction of several drugs in various geographical regions is likely to drive the market during the forecast period. For instance, in October 2016, the FDA granted Breakthrough Therapy Designation to Alecensa (alectinib), a drug developed by Genentech to treat ALK-positive NSCLC as a first-line treatment. The drug has been approved in the U.S., Japan, Canada, Hong Kong, South Korea, Kuwait, and Israel.

Presence of a strong pipeline of drugs for non-small cell lung cancer helps propel the market during the forecast period. Bristol-Myers Squibb Company, Orion Corporation, Merck KGaA, AstraZeneca, F. Hoffmann-La Roche Ltd, and Pfizer, Inc. have major molecules in the pipeline.

Further key findings from the study suggest:

By drug, Alimta accounted for the highest share in 2015. However, it is expected to witness decline in its share during the forecast period.

Alecensa (alectinib) is expected to grow at the highest rate during the forecast period. This is majorly attributed to the clinical benefit of the drug to treat ALK-positive NSCLC.

Alecensa is expected to be a competitor to Pfizer’s Xalkori and Merck’s Keytruda during the forecast period. A superior progression-free survival rate of Alecensa was observed in the clinical trials as compared to Crizotinib.

Geographically, North America dominated the overall industry in 2015. This is due to the early entry of drugs in the market, increased adoption of new treatment, and high cost of the drug.

It is expected that North America would maintain its dominance during the forecast period and grow with the highest rate over the coming years due to expected entry of new drugs.

Several players are operating in the industry. Geographical penetration and development of innovative & effective drugs are the key strategies of the players to increase their share.

Some of the key players are GlaxoSmithKline (GSK) Plc., Novartis AG, AstraZeneca, F. Hoffmann-La Roche AG, Bristol-Myers Squibb, Pfizer Inc., Eli Lilly & Company, and Sanofi.


PLEASE NOTE: This report will be completed after order and will take approximately 1-2 business days after the confirmation of payment.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline (GSK) Plc
  • Novartis
  • Pfizer, Inc.
  • MORE

1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis

2 Executive Summary
2.1 Market Snapshot

3 Non-small Cell Lung Cancer Therapeutics Market Variables, Trends & Scope
3.1 Market Segmentation and Scope
3.1.1 Market driver analysis
3.1.1.1 Strong pipeline
3.1.1.2 Rising prevalence of NSCLC
3.1.2 Market restraint analysis
3.1.2.1 Pricing pressure
3.2 Penetration & Growth Prospects Mapping
3.3 Non-small Cell Lung Cancer Therapeutics Market - PESTLE Analysis
3.4 Industry Analysis - Porter’s
3.5 Non-small Cell Lung Cancer Therapeutics Competitive Scenario, 2015
3.5.1 Competitive landscape: Market position analysis (based on product portfolio, regional presence and strategic initiatives)

4 Non-small Cell Lung Cancer Therapeutics: Drug Estimates & Trend Analysis
4.1 Global Non-small Cell Lung Cancer Therapeutics Market: Drug Movement Analysis & Market Share, 2016 & 2025
4.2 Alimta
4.2.1 Alimta market estimates and forecasts, 2014 - 2025 (USD Million)
4.3 Iressa
4.3.1 Iressa market estimates and forecasts, 2014 - 2025 (USD Million)
4.4 Avastin
4.4.1 Iressa market estimates and forecasts, 2014 - 2025 (USD Million)
4.5 Tarceva
4.5.1 Tarceva market estimates and forecasts, 2014 - 2025 (USD Million)
4.6 Zykadia
4.6.1 Zykadia market estimates and forecasts, 2014 - 2025 (USD Million)
4.7 Tagrisso
4.7.1 Tagrisso market estimates and forecasts, 2014 - 2025 (USD Million)
4.8 Xalkori
4.8.1 Xalkori market estimates and forecasts, 2014 - 2025 (USD Million)
4.9 Cyramza
4.9.1 Cyramza market estimates and forecasts, 2014 - 2025 (USD Million)
4.10 Opdivo
4.10.1 Opdivo market estimates and forecasts, 2014 - 2025 (USD Million)
4.11 Alecensa
4.11.1 Alecensa market estimates and forecasts, 2014 - 2025 (USD Million)

5 Non-small Cell Lung Cancer Therapeutics: Regional Estimates & Trend Analysis
5.1 Regional Movement Analysis & Market Share, 2016 & 2025
5.2 North America
5.2.1 North America non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.2.2 North America non-small cell lung cancer therapeutics market, by country, 2014 - 2025 (USD Million)
5.2.3 U.S.
5.2.3.1 U.S. non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.2.4 Canada
5.2.4.1 Canada non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.3 Europe
5.3.1 Europe non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.3.2 Europe non-small cell lung cancer therapeutics market, by country, 2014 - 2025 (USD Million)
5.3.3 Germany
5.3.3.1 Germany non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.3.4 UK
5.3.4.1 UK non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.4.2 Asia Pacific non-small cell lung cancer therapeutics market, by country, 2014 - 2025 (USD Million)
5.4.3 Japan
5.4.3.1 Japan non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.4.5 China
5.4.5.1 China non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.5 Latin America 5.5.1 Latin America non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.5.2 Latin America non-small cell lung cancer therapeutics market, by country, 2014 - 2025 (USD Million)
5.5.3 Brazil
5.5.3.1 Brazil non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.5.4 Mexico
5.5.4.1 Mexiconon-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.6 MEA
5.6.1 MEA non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
5.6.2 MEA non-small cell lung cancer therapeutics market, by country, 2014 - 2025 (USD Million)
5.6.3 South Africa
5.6.3.1 South Africa non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)

6 Competitive Landscape
6.1 GlaxoSmithKline (GSK) Plc
6.1.1 Company overview
6.1.2 Financial performance
6.1.3 Product benchmarking
6.1.4 Strategic initiatives
6.2 Novartis
6.2.1 Company overview
6.2.2 Financial performance
6.2.3 Product benchmarking
6.2.4 Strategic initiatives
6.3 AstraZeneca
6.3.1 Company overview
6.3.2 Financial performance
6.3.3 Product benchmarking
6.3.4 Strategic initiatives
6.4 F. Hoffmann-La Roche Ltd
6.4.1 Company overview
6.4.2 Financial performance
6.4.3 Product benchmarking
6.4.4 Strategic initiatives
6.5 Bristol Myers Squibb Company
6.5.1 Company overview
6.5.2 Financial performance
6.5.3 Product benchmarking
6.5.4 Strategic initiatives
6.6 Pfizer, Inc.
6.6.1 Company overview
6.6.2 Financial performance
6.6.3 Product benchmarking
6.6.4 Strategic Initiatives
6.7 Eli Lilly and Company
6.7.1 Company overview
6.7.2 Financial performance
6.7.3 Product benchmarking
6.7.4 Strategic initiatives
6.8 Sanofi
6.8.1 Company overview
6.8.2 Financial performance
6.8.3 Product benchmarking
6.8.4 Strategic initiatives

List of Tables

Table 1 Non-small cell cancer therapeutics market - global market current and forecast by regions (2015 - 2024) in (USD Million)
Table 2 North America non-small cell cancer therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
Table 3 North America non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 4 U.S. non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 5 Canada non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 6 Europe non-small cell cancer therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
Table 7 Europe non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 8 UK non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 9 Germany non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 10 Asia Pacific non-small cell cancer therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
Table 11 Asia Pacific non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 12 Japan non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 13 China non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 14 Latin America non-small cell cancer therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
Table 15 Latin America non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 16 Brazil non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 17 Mexico non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 18 MEA non-small cell cancer therapeutics market estimates and forecasts, by country, 2014 - 2025 (USD Million)
Table 19 MEA non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)
Table 20 South Africa non-small cell cancer therapeutics market estimates and forecasts, by drug, 2014 - 2025 (USD Million)

List of Figures

Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain based sizing & Forecasting
Figure 6 QFD modeling for market share assessment
Figure 7 Market summary
Figure 8 Market trends & outlook
Figure 9 Market segmentation & scope
Figure 10 Market driver relevance analysis (Current & future impact)
Figure 11 Market restraint relevance analysis (Current & future impact)
Figure 12 Penetration & growth prospect mapping
Figure 13 Non-small cell lung cancer therapeutics market - PESTLE analysis
Figure 14 Porter’s Five Forces Analysis
Figure 15 Non-small cell lung cancer therapeutics market outlook key takeaways
Figure 16 Non-small cell lung cancer therapeutics market: drug movement analysis
Figure 17 Global non-small cell lung cancer therapeutics market, by drug, 2014 - 2025 (USD Million)
Figure 18 Global Alimta market, 2014 - 2025 (USD Million)
Figure 19 Global Iressa market, 2014 - 2025 (USD Million)
Figure 20 Global Avastin market, 2014 - 2025 (USD Million)
Figure 21 Global Tarceva market, 2014 - 2025 (USD Million)
Figure 22 Global Zykadia market, 2014 - 2025 (USD Million)
Figure 23 Global Tagrisso market, 2014 - 2025 (USD Million)
Figure 24 Global Xalkori market, 2014 - 2025 (USD Million)
Figure 25 Global Cyramza market, 2014 - 2025 (USD Million)
Figure 26 Global Opdivo market, 2014 - 2025 (USD Million)
Figure 27 Global Alecensa market, 2014 - 2025 (USD Million)
Figure 28 Regional market: Key takeaways
Figure 29 Non-small cell lung cancer therapeutics market regional outlook, 2015 & 2025
Figure 30 North America non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 31 U.S. non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 32 Canada non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 33 Europe non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 34 Germany non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 35 UK non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 36 Asia Pacific non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 37 Japan non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 38 China non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 39 Latin America non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 40 Brazil non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 41 Mexico non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 42 Middle East Africa non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)
Figure 43 South Africa non-small cell lung cancer therapeutics market, 2014 - 2025 (USD Million)  
Figure 44 Strategy frameworks

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • GlaxoSmithKline (GSK) Plc
  • Novartis
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Bristol Myers Squibb Company
  • Pfizer, Inc.
  • Eli Lilly and Company
  • Sanofi
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll